Multifunctional Monovalent Copper-Doped Carbon Dots for Synergistic Antibacterial-Antitumor Therapy
Source abstract
Abstract
Current breast cancer treatment regimens are confronted with three major challenges: monotonous therapeutic effects, intratumoral bacterium-induced drug resistance and immunosuppression, and off-target toxicity of drugs. To address these, in this study, a multifunctional nanoplatform of monovalent copper-doped arginine carbon dots (Arg-CuCDs) was developed. From the materials perspective, precisely controlled synthesis conditions enabled stable copper-doped carbon dots in the monovalent state, endowing them with heightened nanoenzyme activity and concurrently achieving red shift of fluorescence emission to the near-infrared region (∼700 nm). This facilitates simultaneous chemodynamic therapy (CDT) and deep tumor imaging. Functionally, its pH-dependent catalytic activity and acidic drug release behavior sensitively respond to the tumor microenvironment (TME) and selectively kill tumor cells. Crucially, Arg-CuCDs exert therapeutic effects by modulating tumor microbial community structure through bacterial membrane disruption, achieving synergistic antibacterial-antitumor therapy. Concurrently, from a disease diagnosis and treatment evaluation perspective, a sensitive fluorescence test strip was developed based on the fluorescence quenching caused by the internal filtration effect triggered by copper-amino coordination, for the dynamic monitoring of dopamine in the TME (the biomarker reflects tumor progression, metabolism, and treatment response). This "one stone, multiple birds" diagnosis and treatment strategy provides a promising strategy for developing emerging breast cancer treatment regimens.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Carbon and Quantum Dots Applications · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy
Chongqing Medical University
Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center
Department of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases
the First Affiliated Hospital of Chongqing Medical University
Funding
Future Medical Youth Innovation Team Support Program of Chongqing Medical University
References (58)
Show source-provided references
1. 10.3390/molecules2719660810.3390/molecules27196608 ↗
2. 10.1177/1073274823120919310.1177/10732748231209193 ↗
3. 10.3389/fimmu.2024.137543310.3389/fimmu.2024.1375433 ↗
4. 10.3390/plants1213249410.3390/plants12132494 ↗
5. 10.1016/j.jddst.2025.10665310.1016/j.jddst.2025.106653 ↗
6. 10.1016/j.bbcan.2022.18884610.1016/j.bbcan.2022.188846 ↗
7. 10.1016/j.cell.2022.02.02710.1016/j.cell.2022.02.027 ↗
8. 10.1016/j.celrep.2022.11162510.1016/j.celrep.2022.111625 ↗
9. 10.1016/j.nantod.2023.10199410.1016/j.nantod.2023.101994 ↗
10. 10.1039/D3TB02362A10.1039/D3TB02362A ↗
11. 10.1016/j.ccell.2023.09.00210.1016/j.ccell.2023.09.002 ↗
12. 10.1016/j.carbon.2020.11.01710.1016/j.carbon.2020.11.017 ↗
13. 10.1002/chem.20150246310.1002/chem.201502463 ↗
14. 10.1016/j.msec.2018.11.06010.1016/j.msec.2018.11.060 ↗
15. 10.1016/j.jconrel.2020.12.02310.1016/j.jconrel.2020.12.023 ↗
16. 10.1002/adhm.20240320110.1002/adhm.202403201 ↗
17. 10.1021/acsami.3c1833110.1021/acsami.3c18331 ↗
18. 10.1021/acsomega.2c0448410.1021/acsomega.2c04484 ↗
19. 10.2147/IJN.S44988710.2147/IJN.S449887 ↗
20. 10.1039/D2NA00269H10.1039/D2NA00269H ↗
21. 10.1002/adhm.20197006010.1002/adhm.201970060 ↗
22. 10.1021/acsnano.3c0136910.1021/acsnano.3c01369 ↗
23. 10.1021/acsnano.3c1022610.1021/acsnano.3c10226 ↗
24. 10.1002/adma.20200224610.1002/adma.202002246 ↗
25. 10.1186/s12951-021-00813-810.1186/s12951-021-00813-8 ↗
26. 10.1021/acsanm.4c0054610.1021/acsanm.4c00546 ↗
27. 10.7150/jca.2085010.7150/jca.20850 ↗
28. 10.1186/s13041-022-00902-110.1186/s13041-022-00902-1 ↗
29. 10.1002/adhm.20230467410.1002/adhm.202304674 ↗
30. 10.1002/smtd.20200106610.1002/smtd.202001066 ↗
31. 10.1002/adhm.20190019210.1002/adhm.201900192 ↗
32. 10.1016/j.carbon.2021.07.06310.1016/j.carbon.2021.07.063 ↗
33. 10.1016/j.cej.2024.15508110.1016/j.cej.2024.155081 ↗
34. 10.1039/C9NR10986B10.1039/C9NR10986B ↗
35. 10.1002/adfm.20251380510.1002/adfm.202513805 ↗
36. 10.1021/acsnano.2c0251810.1021/acsnano.2c02518 ↗
37. 10.1021/jacs.0c0169910.1021/jacs.0c01699 ↗
38. 10.1096/fj.202100273rr10.1096/fj.202100273rr ↗
39. 10.1007/s00726-025-03456-310.1007/s00726-025-03456-3 ↗
40. 10.1002/adma.20180745610.1002/adma.201807456 ↗
41. 10.1002/ange.20191482610.1002/ange.201914826 ↗
42. 10.1021/acs.molpharmaceut.0c0107410.1021/acs.molpharmaceut.0c01074 ↗
43. 10.1371/journal.pone.004706310.1371/journal.pone.0047063 ↗
44. 10.1039/c3mt00151b10.1039/c3mt00151b ↗
45. 10.3389/fonc.2022.86093210.3389/fonc.2022.860932 ↗
46. 10.1021/acsami.1c0892610.1021/acsami.1c08926 ↗
47. 10.1021/acs.est.7b0043410.1021/acs.est.7b00434 ↗
48. 10.1016/j.jconrel.2022.09.02010.1016/j.jconrel.2022.09.020 ↗
49. 10.1016/j.cej.2025.16430810.1016/j.cej.2025.164308 ↗
50. 10.2174/156800961966619080213571410.2174/1568009619666190802135714 ↗
51. 10.1111/jcmm.1480110.1111/jcmm.14801 ↗
52. 10.1002/adfm.20231209210.1002/adfm.202312092 ↗
53. 10.1016/j.foodchem.2021.12965710.1016/j.foodchem.2021.129657 ↗
54. 10.1016/j.jcis.2020.09.02710.1016/j.jcis.2020.09.027 ↗
55. 10.3390/nano1103065210.3390/nano11030652 ↗
56. 10.1016/j.addr.2024.11545810.1016/j.addr.2024.115458 ↗
57. 10.1016/j.cclet.2025.11090710.1016/j.cclet.2025.110907 ↗
58. 10.3389/fcimb.2022.84902210.3389/fcimb.2022.849022 ↗